Your browser doesn't support javascript.
loading
Prognostic impact of FGFR2/3 alterations in patients with biliary tract cancers receiving systemic chemotherapy: the BITCOIN study.
Rizzato, Mario; Brignola, Stefano; Munari, Giada; Gatti, Maura; Dadduzio, Vincenzo; Borga, Chiara; Bergamo, Francesca; Pellino, Antonio; Angerilli, Valentina; Mescoli, Claudia; Guido, Maria; Rearden, Jessica; Gringeri, Enrico; Cillo, Umberto; Dei Tos, Angelo Paolo; Zagonel, Vittorina; Loupakis, Fotios; Lonardi, Sara; Fassan, Matteo.
Afiliação
  • Rizzato M; Medical Oncology 1, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy; Department of Surgical, Oncological, and Gastroenterological Sciences, University of Padua, Padua, Italy.
  • Brignola S; Department of Medicine (DIMED), University of Padua, Padua, Italy; Department of Pathology, Azienda ULSS 2 Marca Trevigiana, Treviso, Italy.
  • Munari G; Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
  • Gatti M; Medical Oncology 1, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
  • Dadduzio V; Medical Oncology 1, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy; Unit of Oncology, Ospedale Monsignor R. Dimiccoli, Barletta, Italy.
  • Borga C; Department of Medicine (DIMED), University of Padua, Padua, Italy.
  • Bergamo F; Medical Oncology 1, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
  • Pellino A; Medical Oncology 1, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy; Department of Surgical, Oncological, and Gastroenterological Sciences, University of Padua, Padua, Italy.
  • Angerilli V; Medical Oncology 1, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
  • Mescoli C; University Hospital of Padua, Padua, Italy.
  • Guido M; Department of Medicine (DIMED), University of Padua, Padua, Italy; Department of Pathology, Azienda ULSS 2 Marca Trevigiana, Treviso, Italy.
  • Rearden J; QED Therapeutics, San Francisco, CA, USA.
  • Gringeri E; Department of Surgical, Oncological, and Gastroenterological Sciences, University of Padua, Padua, Italy.
  • Cillo U; Department of Surgical, Oncological, and Gastroenterological Sciences, University of Padua, Padua, Italy.
  • Dei Tos AP; Department of Medicine (DIMED), University of Padua, Padua, Italy.
  • Zagonel V; Medical Oncology 1, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
  • Loupakis F; Medical Oncology 1, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
  • Lonardi S; Medical Oncology 3, Veneto Institute of Oncology, IOV - IRCCS, Padua, Italy.
  • Fassan M; Department of Medicine (DIMED), University of Padua, Padua, Italy; Veneto Institute of Oncology IOV - IRCCS, Padua, Italy. Electronic address: matteo.fassan@unipd.it.
Eur J Cancer ; 166: 165-175, 2022 05.
Article em En | MEDLINE | ID: mdl-35303508
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias dos Ductos Biliares / Neoplasias do Sistema Biliar / Colangiocarcinoma / Receptor Tipo 2 de Fator de Crescimento de Fibroblastos / Receptor Tipo 3 de Fator de Crescimento de Fibroblastos Idioma: En Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Itália
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias dos Ductos Biliares / Neoplasias do Sistema Biliar / Colangiocarcinoma / Receptor Tipo 2 de Fator de Crescimento de Fibroblastos / Receptor Tipo 3 de Fator de Crescimento de Fibroblastos Idioma: En Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Itália